Author profile
Editorial team for Peptide Therapy Guide.
From this author
Dyax could receive over $100 million in development and sales milestones. Sigma-Tau SpA is paying Dyax $2.5 million in cash and will make a $2.5 million equity investment in the firm as part of a partnership t…
Read guide →Firm also gains an option to license Vaxisome for use with its pipeline vaccines. NasVax entered into a joint research and option for license agreement with Novartis Vaccines and Diagnostics to investigate the…
Read guide →Firm says partnering vaccines will allow it to concentrate on CLIPS-based mAbs. Pepscan is to receive a minority stake in Immunovo as part of the companies’ agreement to partner on development of Pepscan’s the…
Read guide →Alliance targets 11beta-HSD-1 for the treatment of metabolic syndrome disorders. Vitae Pharmaceuticals received a $14 million milestone payment from Boehringer Ingelheim with the initiation of a Phase I trial.…
Read guide →Patient recruitment for trial with expanded neural stem cell product will begin in April. Stem cell therapeutics company ReNeuron raised about £4.7 million (almost $7.3 million) before expenses in a fundraisin…
Read guide →PD01 is designed to trigger antibodies that bind to and clear alpha-synuclein from the brain. AFFiRiS was awarded $1.5 million from the Michael J. Fox Foundation (MJFF) to support a Phase I study with its Park…
Read guide →Rhythm has two clinical-stage candidates for obesity and diabetes. Rhythm obtained $25 million through a Series B financing round. Rhythm will use the proceeds to continue advancing its small-peptide therapeut…
Read guide →Three years after the release of disappointing Phase II results, Novartis is discontinuing the NIC002 project, which focused on a therapeutic vaccine candidate for the treatment of nicotine addiction. As a res…
Read guide →Novartis exercised an option to license Boston-based Lubris’s recombinant human lubricin (proteoglycan 4) candidate, ECF843, for ophthalmic indications worldwide, excluding Europe. ECF843 is in development for…
Read guide →BI will develop firm’s current dual glucagon/GLP-1 agonist as well as new dual agonists. Boehringer Ingelheim (BI) and Zealand Pharma inked an exclusive global license and collaboration agreement centered on d…
Read guide →Despite it’s well known genetic underpinnings, there are currently no drugs to treat the underlying cause of Huntington’s disease (HD). However, a new study reports promising results for a new HD drug that has…
Read guide →Peptide Osterreich Kaufen Exploring Peptide Osterreich Kaufen:Formulation Design and Compatibility Sustained growth within this sector reshapes technical standards for raw peptide evaluation and quality contro…
Read guide →Research Corporation Technologies (RCT) is tapping Isogenica for use of the latter’s CIS display platform to screen its antibody-derived engineered CH2 domain libraries. The libraries are the foundation of a b…
Read guide →Biotecnol and PolyTherics formed a collaboration that aims to develop multispecific anticancer Tribody-drug conjugates (TDCs) that consist of Biotecnol’s Tribody molecules linked to cytotoxic payloads attached…
Read guide →The National Institute of Mental Health awarded Omeros a roughly $700,000 grant to support the application of its DTLacO platform for the development of orphan GPCR-targeting antibodies against neurological di…
Read guide →Oxford BioTherapeutics (OBT) will develop new cancer drugs with Boehringer Ingelheim (BI) by identifying new antibody targets, then granting BI rights to develop and commercialize the resulting new antibody pr…
Read guide →Peptide Kliniek Peptide Kliniek Revisiting:Empirical Data of Bench Experimentation Deepening molecular biological research creates new theoretical blueprints for precise peptide engineering and controllable ta…
Read guide →Partnership will combine PEGylation platform with autoantibody-binding blocker. PolyTherics is teaming up with researchers at University College London (UCL) in the U.K. to develop a new protein-based therapy …
Read guide →Novartis signed an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline. The fully human monoclonal antibody, which targets the CD20 molecule, is being developed for relapsing remitting…
Read guide →Addressing Moderna’s annual R&D Day earlier this month, during which the company updates investors on its pipeline progress, CEO Stéphane Bancel summarized his company’s vision of advancing messenger RNA (mRNA…
Read guide →